Objective
Allergic asthma is a disease of airway inflammation caused by an allergic reaction to an antigen. Pathogenic CD4+ T helper type 2 (Th2) cells in lungs are involved in the initiation and perpetuation of the allergic response in airways of asthmatics and animals. Mouse models generated by systemic immunization and respiratory tract exposure with inhaled antigen or by adoptive transfer of effector Th2 cells into naive mice develop eosinophilic inflammation, mucus hypersecretion, and airway hyperreactivity. To mimic disease in asthmatics, we developed a relapsing-remitting mouse model, in we investigate mice during remission and secondary antigen lung challenge induced relapses. Recovered mice are characterized by the presence of Th2 memory lymphocytes in lungs for their lifetime. Exposure of recuperated mice to inhaled allergen reactivates these lung CD4+ Th2 memory cells, consequently initiating disease relapse. The factors governing the survival and retention of CD4+ Th2 cells in the lungs are unknown. One possibility is that memory CD4+ Th2 cells are retained in the lungs by chemokine- chemokine receptor (CKR) interactions. The objective of this project is to identify key chemokine-CKR interactions that control the migration of Th2 cells. We propose specifically, 1) to determine CKR expression on resting CD4+ T cells in the lungs during remission and correlate phenotype with effector function; 2) to identify the critical CKR expression on Th2 cells allowing them to immigrate from the lung during antigen exposure; and 3) to define antigen-specific Th2 cells using a novel transgenic adoptive transfer system. Discovering a reliable phenotype that distinguishes memory Th2 cells in the lungs would allow for their isolation and characterization and potentially lead to new approaches to prevent disease relapses and progression of allergic asthma.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine pneumology asthma
- medical and health sciences basic medicine immunology immunisation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2007-4-2-IIF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
1090 Wien
Austria
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.